Genome-wide analyses of pediatric brain tumors have recently provided comprehensive insights into the underlying biology driving tumor development in the recent past. These advances are urgently needed to help improve the treatment of children with brain tumors. Notably, malignant brain tumors now constitute the number one cause of death in childhood cancer patients, despite aggressive treatment strategies consisting of surgical resection, cranio-spinal radiation and high-dose chemotherapy regiments.
Our main goal is to characterize tumor-specific alterations affecting the coding and non-coding genome to refine existing or develop novel treatment strategies. Specifically, we perform genome-wide profiling and next-generation sequencing studies paired with functional modeling to identify oncogenic drivers that are amenable for molecularly targeted therapies or to the improve disease classification through biomarker discovery.
We are part of the German Cancer Consotium (DKTK) and the German Cancer Research Center (DKFZ) as a DKTK junior research group within the DKTK partnersite Essen/Düsseldorf: http://www.dkfz.de/de/dktk/Personen/Remke.html